Quick answers
- What is Ivabradine used for?
- The FDA-approved label (Corlanor, Amgen Inc, November 10, 2025) says: “1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ivabradine have a boxed warning?
- No. None of the 12 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Ivabradine?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated March 24, 2026). Ask your pharmacist about alternatives.
- Has Ivabradine been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started June 4, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Ivabradine?
- 12 companies list prescription products of Ivabradine in the FDA NDC Directory, including Amgen, Inc, Novadoz Pharmaceuticals LLC and NorthStar Rx LLC.
What Ivabradine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. …
— FDA label: Corlanor, Amgen Inc, effective November 10, 2025. Read the full label on DailyMed →
The FDA has 12 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 12 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet · Solution |
|---|---|
| Route | Oral |
| Prescription products | 24 in the FDA NDC Directory |
| Brand names | Corlanor |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ivabradine hydrochloride 5 mg tablet | Generic | $0.7103 per tablet |
| ivabradine hydrochloride 5 mg tablet, film coated | Generic | $0.7103 per tablet |
| ivabradine hydrochloride 5 mg tablet, film coated | Brand: Corlanor | $10.00 per tablet |
| ivabradine hydrochloride 7.5 mg tablet | Generic | $0.6026 per tablet |
| ivabradine hydrochloride 7.5 mg tablet, film coated | Generic | $0.6026 per tablet |
| ivabradine hydrochloride 7.5 mg tablet, film coated | Brand: Corlanor | $10.02 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Amgen, Inc3 products
- Novadoz Pharmaceuticals LLC2 products
- NorthStar Rx LLC2 products
- Camber Pharmaceuticals, Inc.2 products
- Ingenus Pharmaceuticals, LLC2 products
- Alembic Pharmaceuticals Inc.2 products
- Zydus Lifesciences Limited2 products
- Alembic Pharmaceuticals Limited2 products
- Golden State Medical Supply, Inc.2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Bionpharma Inc.2 products
- American Health Packaging1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA206143 CORLANOR | Amgen Inc | April 15, 2015 | 4, latest August 4, 2021 2021: Labeling · 2019: Labeling · 2017: Labeling |
| NDA209964 CORLANOR | Amgen Inc | April 22, 2019 | 1, latest August 4, 2021 2021: Labeling |
Generic approvals (6)
- ANDA214051Ingenus Pharms LLC · December 30, 2021
- ANDA213366Annora Pharma · October 5, 2022
- ANDA213442Zydus Pharms · November 29, 2023
- ANDA213276Bionpharma · September 5, 2024
- ANDA215238Alembic · November 8, 2024
- ANDA213483Msn · April 28, 2025
Shortage status
To be discontinued · updated March 24, 2026 · first posted March 24, 2026
| Product | Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60) |
|---|---|
| Company | Amgen Inc. |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
June 4, 2026 · Class II · Ongoing · D-0612-2026
Presence of Foreign Substance.
Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. — Amgen, Inc.
-
June 4, 2026 · Class II · Ongoing · D-0615-2026
Presence of Foreign Substance.
Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60 — Amgen, Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Corlanor, Amgen Inc, effective November 10, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →